Search for a command to run...
AstraZeneca PLC
Drug Manufacturers - General
| Date | Politician | Asset | Action | Amount | Trade Price | 30D Price | 1M Return | Alpha | 1M Prediction |
|---|---|---|---|---|---|---|---|---|---|
Mar 13, 2026 |  Rohit KhannaD | Stock | Buy |
| $1,001 - $15,000 |
| $189.90 |
| $204.03 |
| +7.4% |
| +4.6% |
Feb 13, 2026 | Rohit KhannaD | Stock | Sell | $15,001 - $50,000 | $203.43 | $189.90 | -6.7% | -3.8% |
Dec 18, 2025 |  Gilbert CisnerosD | Stock | Buy | $1,001 - $15,000 | $179.35 | $186.83 | +4.2% | +1.6% |
Dec 8, 2025 |  Julia LetlowR | Stock | Buy | $1,001 - $15,000 | $180.68 | $188.36 | +4.3% | +3.1% |
Nov 19, 2025 | Gilbert CisnerosD | Stock | Buy | $1,001 - $15,000 | $176.14 | $180.83 | +2.7% | -0.4% |
Oct 31, 2025 |  Lisa McClainR | Stock | Sell | $1,001 - $15,000 | $163.10 | $183.53 | +12.5% | +12.3% |
Oct 30, 2025 | Lisa McClainR | Stock | Sell | $1,001 - $15,000 | $162.98 | $183.53 | +12.6% | +12.1% |
Oct 30, 2025 | Lisa McClainR | Stock | Buy | $1,001 - $15,000 | $162.98 | $183.53 | +12.6% | +12.1% |
Oct 21, 2025 | Gilbert CisnerosD | Stock | Buy | $1,001 - $15,000 | $164.72 | $175.53 | +6.6% | +9.4% |
Sep 23, 2025 |  Valerie HoyleD | Stock | Sell | $1,001 - $15,000 | $150.37 | $165.08 | +9.8% | +8.5% |
Jul 22, 2025 | Lisa McClainR | Stock | Buy | $1,001 - $15,000 | $138.54 | $159.26 | +15.0% | +13.9% |
Jun 17, 2025 | Lisa McClainR | Stock | Sell | $1,001 - $15,000 | $139.51 | $136.14 | -2.4% | -7.8% |
Jun 9, 2025 | Lisa McClainR | Stock | Buy | $1,001 - $15,000 | $143.52 | $139.21 | -3.0% | -7.4% |
Apr 21, 2025 |  Bruce WestermanR | Stock | Sell | $1,001 - $15,000 | $131.50 | $136.97 | +4.2% | -9.3% |
Mar 12, 2025 | Rohit KhannaD | Option | Buy | $1,001 - $15,000 | $148.55 | $130.31 | -12.3% | -8.1% |
Mar 3, 2025 | Bruce WestermanR | Stock | Buy | $1,001 - $15,000 | $149.59 | $141.96 | -5.1% | -2.1% |
Oct 29, 2024 | Valerie HoyleD | Stock | Buy | $1,001 - $15,000 | $73.65 | $65.80 | -10.7% | -13.6% |
Compass Therapeutics: Potential Here, But Patience Required
Abivax: Maintaining 'Strong Buy' On Buyout Speculation And Obefazimod Advancement
Europe Approves AstraZeneca's Imfinzi (Durvalumab) Combined With FLOT Chemotherapy For Resectable, Early-Stage, And Locally Advanced Gastric And Gastroesophageal Junction Cancers
Mineralys: Big Pharma Threatens To Undermine Likely Hypertension Drug Approval
'Abivax Denies French Media Report Of Astrazeneca Takeover' - CNBC